TRANSITIONAL CELL CARCINOMA
Clinical trials for TRANSITIONAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new TRANSITIONAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for TRANSITIONAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Matched conditions: TRANSITIONAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for tough bladder cancer
Disease control OngoingThis study tests a combination of three drugs—ixazomib, gemcitabine, and doxorubicin—in people with advanced bladder cancer that has spread or cannot be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors. About 57 adults will take part …
Matched conditions: TRANSITIONAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC